At-home cancer screening kits, particularly those for colon cancer, have gained traction in recent years. “To my knowledge, ...
Earlier this year, the United States Department of Health and Human Services Office of the Inspector General (HHS OIG) ...
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
The nonsteroidal anti-inflammatory drug (NSAID) flunixin meglumine has been approved by the FDA for fever associated with ...
The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...
Northwestern Medicine, Chicago's premier integrated academic health system, and Vitestro, a pioneer in autonomous robotic vascular access ...
In particular, AI could assist FDA staff to review drug and device applications, he told senators on the Health, Education, ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...
A new Northwestern Medicine study publishing in Nature Medicine suggests a promising alternative to previous attempts to ...
NIST's fecal RM helps standardize microbiome research to ensure accuracy, consistency, comparability, and reproducibility in the field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback